1995
DOI: 10.1007/bf02310353
|View full text |Cite
|
Sign up to set email alerts
|

Efficacy and safety of azithromycin versus benzylpenicillin or erythromycin in community-acquired pneumonia

Abstract: Azithromycin, a recently introduced antibiotic, offers the potential advantages of short-course administration and lower toxicity compared to other macrolides. Approved for the treatment of mild pneumonia, this drug was investigated in a study of patients hospitalized for community-acquired pneumonia. In an open-labelled randomized study, oral azithromycin was compared with intravenous benzylpenicillin in patients suspected to have pneumococcal pneumonia. Azithromycin was also compared with erythromycin, both … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
27
0
3

Year Published

2002
2002
2015
2015

Publication Types

Select...
6
3

Relationship

0
9

Authors

Journals

citations
Cited by 60 publications
(31 citation statements)
references
References 13 publications
1
27
0
3
Order By: Relevance
“…In numerous recent clinical trials of CAP, macrolides were as effective as comparators (b-lactam or FQ antibiotics; clinical success rates of 77%-95% with macrolides [179,[187][188][189][190] and 70%-100% with comparators [178,[191][192][193][194][195][196][197]). However, in one multicenter randomized trial in Scandinavia, roxithromycin was less effective than sparfloxacin (clinical response rates in 79% and 94%, respectively) [194].…”
Section: Trials Of Macrolides For Capmentioning
confidence: 99%
“…In numerous recent clinical trials of CAP, macrolides were as effective as comparators (b-lactam or FQ antibiotics; clinical success rates of 77%-95% with macrolides [179,[187][188][189][190] and 70%-100% with comparators [178,[191][192][193][194][195][196][197]). However, in one multicenter randomized trial in Scandinavia, roxithromycin was less effective than sparfloxacin (clinical response rates in 79% and 94%, respectively) [194].…”
Section: Trials Of Macrolides For Capmentioning
confidence: 99%
“…Thirteen studies have evaluated the efficacy of azithromycin in 1576 patients with community acquired pneumonia [10][11][12][13][14][15][16][17][18][19][20]22]. These open studies compared treatment with azithromycin to benzyl penicillin, erythromycin, cefaclor, roxithromycin or amoxicillin/clavulanate and determined that azithromycin was as effective and as well tolerated as other antimicrobial drugs.…”
Section: Discussionmentioning
confidence: 99%
“…Pulmonary concentrations of azithromycin remain well above minimal inhibitory concentrations (MIC) of the most important respiratory pathogens for 4 days after the administration of a single 500 mg dose [9]. Several comparative [10][11][12][13][14][15][16][17][18][19][20] clinical studies for treating CAP have been performed in which azithromycin has been administered for 3 days [10][11][12]15,16,19] or 5 days [10,13,14,17,18,20]. Despite the advantages of azithromycin, its role in CAP is unclear and so in this study we compared the efficacy and safety of 3 days treatment with azithromycin with conventional therapy used by the primary physician for treating CAP.…”
Section: Introductionmentioning
confidence: 99%
“…The clinical and bacteriological results of selected trials are summarized in Table 4 [140][141][142][143][144][145][146][147][148][149][150]. Overall, clinical success rates ranging from 81-100 and 86-97% were observed with azithromycin and clarithromycin, respectively; bacteriological success ranged from 80-94 and 89-95% respectively.…”
Section: Advantagesmentioning
confidence: 99%